Session 7 – Cell & Gene Therapies
Date: 26 July (Friday) 9:00 – 12:00 Venue: 3F, Bldg. A, CTBC Financial Park, Ballroom A
Jonas C. Wang, Ph.D.
Chairman/Chief Executive Officer,
StemCyte International Ltd
Dr. Jonas Wang is the Chairman/CEO of StemCyte International Ltd (SIL). Before joining SIL, he was a Partner of Sycamore Ventures responsible for life sciences and biotechnology investments in 2002-2014.
Before joining Sycamore Ventures, Jonas was Vice President of Research and Technology at Johnson & Johnson Consumer Products and a Corporate Director of J&J Drug Delivery Technology Resource Center (TRC), responsible for new product technology, patent strategy, competitive intelligence, and new measurement methodology for skin and hair care franchise. Prior to that, he was an Associate Director of Basic Pharmaceutics, the Pharmaceutical Research Institute of Bristol-Myers Squibb Co.
In 2001, he had participated at the Congressional Business Summit in Washington, D. C., to lead a business group exploring emerging markets potential in America. Jonas has over 35 years of experience in pharmaceutical R&D management and business development. He was also a member of J&J Consumer Product Worldwide’s L&A Committee and was the key driver for several major acquisitions i.e., ROC & Neutrogena. He has published extensively in drug delivery field and received several major awards in his field, including the Johnson Medal, the highest technical achievement award at J&J, for one of his inventions: anti-wrinkle cream; the Distinguished Alumni awards from the National Defense Medical Center and College of Pharmacy at University of Iowa. During his career with J&J, Jonas developed more than 10 core technologies, and filed more than 30 business-related patents. He is a seasoned versatile executive with experience in start-ups, big Pharma, medical devices, and biotechnology firms. He is experienced with strong Scientific/Regulatory and Business Management background in both pharmaceutical and biotech field. He is expert in developing pharmaceutical patents, business and financial Strategies. He has extensive business contacts in both pharma and biotech field.
Jonas received his Ph.D. in Physical Pharmacy from College of Pharmacy, University of Iowa, USA in 1982 and B.S. Pharmacy degree from National Defense Medical Center in Taiwan, Republic of China. Session Speech Title & Synopsis: Translational Research and Therapeutic Applications of Cell-based regenerative therapies
The regenerative medicine industry has been rapidly expanding over the past few years, making it a high-value, fast-growth market. Key drivers for the market include high rates of clinical trials, accelerated pathways for product approvals, new technologies to support cell and gene therapy manufacturing, and the potential for cell therapies to revolutionize healthcare. With swelling momentum to support the regenerative cell therapy, now a total of ~1028 active cell-based therapy clinical trials have been identified and characterized based on cell type, target indication and trial phase. Multiple technologies have been assessed for the manufacture of these cell types in order to facilitate product translation and future process development. Now approx. 906 companies and cell research institutes are developing regenerative Cell therapy, Immuno-oncology, Genetic Modified Biologics and Tissue Engineering for therapeutic use. The global regenerative medicine market is projected to reach $30.24 Billion by 2022. Cell Therapy segment is expected to dominate the market through the forecast period. North America is leading the global market and is expected to remain dominant until 2022. The North American regenerative market is expected to grow at a CAGR of 32.5%, from 2016-2022. Europe is the 2nd most attractive market for new entrants in the regenerative medicine market, which is expected to grow at a CAGR of 31.2%. Asia Pacific region is growing at a CAGR of 39.9%. Regenerative medicine offers a transformative approach to healthcare, with the potential to not only treat, but cure disease. With such an ever-increasing number of cell-based therapies in the pipeline this industry, if properly developed, it has the potential to make a large contribution toward currently unmet medical need as well as to provide significant health and financial benefits throughout the world.
This talk provides a snapshot of current cell-based therapy clinical trials by cell type, target clinical indication and trial phase and a comparative assessment of the process technology available to manufacture these cell-based therapies. The aim is twofold, firstly to inform industry of current clinical activity involving their cell type. And secondly to identify the challenges associated with the challenges in the translation and commercialization of cell therapies. This analysis will provide a comparison tool for manufacturing technology and facilitate the development clinical indication specific quality assays by providing an overview of the current target clinical indications for cell-based therapies. A StemCyte case study: Phase II IND clinical trial and manufacture of Mononuclear cells (MNC) will be shared in this talk.